A Phase 1b, Open Label, Dose Finding Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Axitinib (Ag-013736) In Combination With Pembrolizumab (Mk-3475) In Patients With Advanced Renal Cell Cancer
Phase of Trial: Phase I
Latest Information Update: 30 Aug 2019
Price : $35 *
At a glance
- Drugs Axitinib (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Acronyms KEYNOTE-035
- Sponsors Pfizer
- 11 Aug 2019 Status changed from active, no longer recruiting to completed.
- 20 Jun 2019 Planned End Date changed from 1 Feb 2019 to 26 Jun 2019.
- 03 Apr 2019 Results assessing immune-related biomarker presented at the 110th Annual Meeting of the American Association for Cancer Research.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History